July 25, 2016
On Friday, July 22nd, The Alliance for Safe Biologic Medicines and MedChi, the Maryland State Medical Society co-hosted a forum entitled “Biosimilars: New Choices, New Challenges”. The event was attended by more than 45 physicians, legislators, patient advocates, healthcare workers, and others. MedChi’s CEO, Gene Ransom III began the forum with a discussion of the importance of biosimilars […]
July 25, 2016
On Friday, July 22nd, The Alliance for Safe Biologic Medicines and MedChi, the Maryland State Medical Society co-hosted a forum entitled “Biosimilars: New Choices, New Challenges”. The event was attended by more than 45 physicians, legislators, patient advocates, healthcare workers, and others. MedChi’s CEO, Gene Ransom III began the forum with a discussion of the importance of biosimilars […]
July 8, 2016
In this video, patient advocate Kathleen Arntsen, President and CEO of the Lupus and Allied Diseases Association (LADA) and an autoimmune patient herself, discusses the power of advocacy and her concerns with Non-Medical Switching (NMS). NMS is the switching of a patient from one treatment to another, typically by a third party such as a Pharmacy Benefit Manager (PBM) […]
July 8, 2016
In this video, patient advocate Kathleen Arntsen, President and CEO of the Lupus and Allied Diseases Association (LADA) and an autoimmune patient herself, discusses the power of advocacy and her concerns with Non-Medical Switching (NMS). NMS is the switching of a patient from one treatment to another, typically by a third party such as a Pharmacy Benefit Manager (PBM) […]
July 6, 2016
ASBM was an exhibitor during the 52nd Annual meeting of the Drug Information Association (DIA) held June 26th-30th in Philadelphia. ASBM members and staff discussed biosimilars policy with attendees, including the need for the FDA to maintain high standards for safety and efficacy when approving biosimilars. More than 65 attendees, including clinical researchers, physicians, pharmacists, […]
July 6, 2016
On June 29th, ASBM Chairman Harry L. Gewanter, MD and ASBM Steering Committee Member Andrew Spiegel, Executive Director of the Global Colon Cancer Association, gave presentations at the 6th Latin American Forum on Biosimilars, held in Brasília, Brazil. The event was also the 7th Brazilian Forum on Biosimilars. The event was attended by more than 500 […]
July 6, 2016
On June 29th, ASBM Chairman Harry L. Gewanter, MD and ASBM Steering Committee Member Andrew Spiegel, Executive Director of the Global Colon Cancer Association, gave presentations at the 6th Latin American Forum on Biosimilars, held in Brasília, Brazil. The event was also the 7th Brazilian Forum on Biosimilars. The event was attended by more than 500 […]
June 18, 2016
Biosimilar drugs hold advantages for people like me, just as biologic medicines have for millions living with life-threatening and life-diminishing diseases. Access to appropriate medication can dramatically improve disease outcome and quality of life. As more biosimilars become available, we want to ensure they are safe and affordable. I strongly support S6311 and A8648A, which […]
June 18, 2016
Biosimilar drugs hold advantages for people like me, just as biologic medicines have for millions living with life-threatening and life-diminishing diseases. Access to appropriate medication can dramatically improve disease outcome and quality of life. As more biosimilars become available, we want to ensure they are safe and affordable. I strongly support S6311 and A8648A, which […]
June 8, 2016
June 8, 2016 By Joe Bova, M.S., R.Ph. Biologic medicines currently help millions of patients suffering from serious conditions like cancer, multiple sclerosis and rheumatoid arthritis. New medicines called biosimilars, which attempt to mimic the therapeutic properties of the original biologics, are becoming available. These will create new treatment options — and cost savings — […]
